[artículo] 
inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 636-644

Título :	Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment
Tipo de documento:	texto impreso
Autores:	John R. Walker, Autor ; Michael Van Ameringen, Autor ; Richard Swinson, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 636-644
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Trastornos fóbicos, Inhibidores selectivos de la recaptación de serotonina, Sertralina.
Resumen:	The aim of this study was to evaluate the efficacy, tolerability, and effects on quality of life of sertraline, a selective serotonin reuptake inhibitor, in the prevention of relapse of generalized social phobia. Fifty adult outpatients with generalized social phobia who were rated much or very much improved on the Clinical Global Impression Scale of Improvement (CGI-I) after 20 weeks of sertraline treatment (50-200 mg/day) were randomly assigned in a one-to-one ratio to either continue double-blind treatment with sertraline or immediately switch to placebo for another 24 weeks.
Link:	./index.php?lvl=notice_display&id=31154

[artículo] Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment [texto impreso] / John R. Walker, Autor ; Michael Van Ameringen, Autor ; Richard Swinson, Autor . - 2023 . - pp. 636-644.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 636-644

Palabras clave:	Trastornos fóbicos, Inhibidores selectivos de la recaptación de serotonina, Sertralina.
Resumen:	The aim of this study was to evaluate the efficacy, tolerability, and effects on quality of life of sertraline, a selective serotonin reuptake inhibitor, in the prevention of relapse of generalized social phobia. Fifty adult outpatients with generalized social phobia who were rated much or very much improved on the Clinical Global Impression Scale of Improvement (CGI-I) after 20 weeks of sertraline treatment (50-200 mg/day) were randomly assigned in a one-to-one ratio to either continue double-blind treatment with sertraline or immediately switch to placebo for another 24 weeks.
Link:	./index.php?lvl=notice_display&id=31154